Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Acalabrutinib Lenalidomide and Rituximab for the Treatment of CD20 Positive Stage III-IV Grade 1-3a Follicular Lymphoma

Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib, lenalidomide, and rituximab may help to control the disease.

human chorionic gonadotropin
ct scan
stage iv grade 2 follicular lymphoma
grade 2 follicular lymphoma
acalabrutinib
  • 0 views
  • 16 Feb, 2024
  • 1 location
Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer.

A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (Part 1), followed by sequential immune targeting with programmed death-ligand (PD-L)1 blockade in combination with low-dose Lenalidomide (Part 2) in patients …

breast ductal carcinoma
azacitidine
blockade
lenalidomide
paclitaxel
  • 0 views
  • 16 Feb, 2024
  • 8 locations
Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

To evaluate the efficacy and safety of TR2-ICE sequential Tirelarizin, lenalidomide alone, or both maintenance therapy in the rescue of patients with relapsed and refractory diffuse large B or high-grade B-cell lymphoma.

  • 0 views
  • 21 Sep, 2021
  • 1 location
Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients

The purpose of this study is to evaluate the safety and efficacy of BiRd regimen combined with BCMA CAR T cell therapy in newly diagnosed multiple myeloma patients

ejection fraction
cellular therapy
lenalidomide
dexamethasone
clarithromycin
  • 0 views
  • 16 Feb, 2024
  • 1 location
Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

multiple myeloma
measurable disease
  • 0 views
  • 05 Aug, 2020
Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas

Describe the treatment of B-cell non-Hodgkin lymphoma patients who receive lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs), and evaluate the efficacy and safety of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs) in the real-world setting.

b-cell lymphoma
lenalidomide
rituximab
hodgkin's disease
non-hodgkin lymphoma
  • 0 views
  • 16 Feb, 2024
  • 1 location